{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 7,
  "pageCount": 53,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "This is a page from a formal report or legal document, likely a Congressional Committee report.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/7",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The Committee’s investigation has uncovered evidence that McKinsey consultants advised FDA on opioid-related regulatory matters at the same time they were advising Purdue and other opioid manufacturers on sales and regulatory strategies involving FDA.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49a-479d168c5f52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.764,
        "x": 0.118,
        "y": 0.551
      },
      "kind": "paragraph",
      "text": "Although McKinsey has failed to produce certain responsive documents related to its conflicts of interest, the documents the Committee has obtained illustrate pervasive conflicts of interest at the company. These documents reveal that at least 22 McKinsey consultants worked for both FDA and opioid manufacturers, including several of McKinsey’s senior-most partners in",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f408802-f92e-4da6-8bd3-f27506c7fab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.764,
        "x": 0.118,
        "y": 0.481
      },
      "kind": "paragraph",
      "text": "The Committee’s investigation has uncovered evidence that McKinsey consultants advised FDA on opioid-related regulatory matters at the same time they were advising Purdue and other opioid manufacturers on sales and regulatory strategies involving FDA.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac9a1bdb-1edb-4fc8-b8da-1713c2a72bbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.764,
        "x": 0.118,
        "y": 0.635
      },
      "kind": "source-note",
      "text": "3 Letter from Chairwoman Carolyn B. Maloney... 4 The Committee has released selected documents... 5 Id. In its November 5, 2021, request letter...",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54f28300-78f1-4ae2-8c03-be4418d23344",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.764,
        "x": 0.118,
        "y": 0.428
      },
      "kind": "title",
      "text": "A. McKinsey Consultants Engaged in Overlapping Work for Opioid Manufacturers and FDA",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7de4af7-18f9-43c6-be2f-32af2e6742bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.135,
        "x": 0.118,
        "y": 0.396
      },
      "kind": "title",
      "text": "II. FINDINGS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a63bfa8-1cfd-49ed-8bd6-b392474443b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6847df5a-d81e-49f9-b2b2-7891fc12c2bb",
      "evidence": "The Committee’s investigation has uncovered evidence that McKinsey consultants advised FDA on opioid-related regulatory matters at the same time they were advising Purdue and other opioid manufacturers on sales",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}